GDX vs XBI
VanEck Gold Miners ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.51% for GDX.
- • GDX pays a higher dividend yield (0.72%).
Side-by-side metrics
| Metric | GDX | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.51% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.72% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $27.26B | $8.30B |
YTD return | 7.78% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.74 | 1.09 |
P/E ratio | 17.92 | — |
Last price | $91.72 | $133.66 |
Inception | — | — |
Issuer | VanEck | State Street |
GDX top holdings
| AEM.TO | Agnico Eagle Mines Ltd | 11.54% |
| NEM | Newmont Corp | 11.31% |
| ABX.TO | Barrick Mining Corp | 7.60% |
| FNV.TO | Franco-Nevada Corp | 5.05% |
| AU | Anglogold Ashanti PLC | 5.00% |
| WPM.TO | Wheaton Precious Metals Corp | 4.93% |
| K.TO | Kinross Gold Corp | 4.84% |
| GFI | Gold Fields Ltd ADR | 4.33% |
| PAAS.TO | Pan American Silver Corp | 3.17% |
| NST.AX | Northern Star Resources Ltd | 2.89% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About GDX
GDX (VanEck Gold Miners ETF) is Major gold mining companies. Managed by VanEck, the fund carries $27.3B in assets under management, an expense ratio of 0.51%, a dividend yield of 0.72%. Its largest holding is Agnico Eagle Mines Ltd (AEM.TO), which represents 11.5% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.